Remedium Bio announces the publication of preclinical data demonstrating the performance of its adjustable dose gene therapy platform – Prometheus™
Posted:
Prometheus™ was specifically designed as a subcutaneously injected gene delivery system, utilizing the same route of administration as most current therapeutic biologics. Remedium is applying the Prometheus™ platform technology to the development of its lead candidate RMD1202, a single injection disease-modifying treatment for type 2 diabetes and obesity.
A wave of British scientific breakthroughs is poised to transform how prostate cancer is found and treated.
Prostate cancer is the most common cancer in men across the UK, and the second most common cause of cancer deaths after lung cancer. …
Free live virtual Learna Open Day for healthcare professionals considering postgraduate study. See how online study works, view the platform live, and submit questions. Wed 11 Feb, 13:00 GMT.
Read more and register here.
Attendees
Sponsors and Exhibitors
Contact us